cirujano oftalmólogo

 

Dr. Francisco Antonio Pugliese Rojas

Cirujano Oftalmólogo

Formación académica

 

– Médico Cirujano Universidad de Carabobo, Valencia, Venezuela.

– Especialista en Oftalmología. Ministerio de Sanidad del Gobierno de España, Madrid, España.

– Médico general. Policlínica el Morro, Valencia, Venezuela.

– Médico general. Instituto Carabobeño para la Salud, Valencia, Venezuela.

– Médico residente de Oftalmología. Hospital Dr. Miguel Pérez Carreño, Caracas, Venezuela.

– Médico residente. Hospital de Especialidades N° 1 de las Fuerzas Armadas, Quito, Ecuador.

– Médico residente de Oftalmología. Hospital Universitario Reina Sofía, Córdoba, España.

– Facultativo Especialista de Área en Oftalmología. Hospital Universitario Reina Sofía, Córdoba, España .

Cursos y congresos

 

– XX Curso de Ciencias Básicas en Oftalmología «Dra. Silvia Salinas», Sociedad Venezolana de Oftalmología, Caracas, Venezuela 2015.

– Curso de Ecografía Ocular, Clínica Santa Lucia, Quito, Ecuador 2016.

– XXI Congreso Ecuatoriano de Oftalmología, Sociedad Ecuatoriana de Oftalmología, Cuenca, Ecuador 2016.

– Primer Taller Teórico Práctico sobre Diagnóstico en Glaucoma, Sociedad Ecuatoriana de Oftalmología, Quito, Ecuador 2016.

– II Curso Bascom Palmer, Sociedad Ecuatoriana de Oftalmología e Instituto Oftalmológico Bascom Palmer, Quito, Ecuador 2017.

– III Curso teórico-práctico del tratamiento del queratocono, Hospital Universitario Reina Sofía, Córdoba, España 2018.

– Curso de Introducción a las Emergencias para Especialistas Internos Residentes, Hospital Universitario Reina Sofía, Córdoba, España 2018.

– XXI Curso Nacional de Iniciación a la Refracción para Residentes de Oftalmología, Hospital Universitario Gregorio Marañón, Madrid, España 2018.

– I Encuentro de casos quirúrgicos en glaucoma, Hospital Universitario Reina Sofía, Córdoba, España 2018.

– LI Congreso de la Sociedad Andaluza de Oftalmología, Córdoba, España 2019.

– XXXII Curso monográfico de iniciación a la oftalmología, Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense, Madrid, España 2019.

– II Encuentro de casos quirúrgicos en glaucoma, Hospital Universitario Reina Sofía, Córdoba, España 2019.

– Curso de Investigación en Salud, Junta de Andalucía, Sevilla, España 2020.

– Webinar de Ecografía Oftalmológica, Fundación Instituto de Investigación Sanitaria, Santiago de Compostela, España 2020.

– Curso de Glaucoma, Universidad de Valladolid, España 2020.

– Curso de actualización en imagen multimodal en patología de retina, Bayer, Barcelona, España 2021.

– XXIV Congreso de la Sociedad Española de Retina y Vítreo, Burgos, España 2021.

– IV Oculoplástica Sin Fronteras, Sociedad Panamericana de Oculoplastia, Punta Cana, República Dominicana 2021.

– Fórum Arruzafa 22ª edición: Manual de Supervivencia en Retina Médica y Cirugía Vítreorretiniana, Hospital La Arruzafa, Córdoba, España 2021.

– Soporte Vital Inmediato, Consejo Europeo de Resucitación, Córdoba, España 2021

– Protección radiológica, IAVANTE, Fundación Progreso y Salud, Córdoba, España 2021

– Volver a lo básico Barcelona Oculoplastics, Instituto de Microcirugía Ocular, Barcelona, España 2022.

– Barcelona Oculoplastics 5ª edición, Instituto de Microcirugía Ocular, Barcelona, España 2022.

reconocimientos

 

– 10 MEJORES PÓSTER de los presentados durante el LI Congreso de la Sociedad Andaluza 2019.

– Aprobación de los exámenes de Óptica, Refracción e Instrumentos en Oftalmología; Ciencias Visuales en Oftalmología y Oftalmología Clínica del Consejo Internacional de Oftalmología 2020 – 2021.

publicaciones

 

– Autor de los capítulos 1, 5 y 10 del libro Algoritmos en Oftalmología para Atención Primaria Laboratorios Esteve, Editorial CeGe, ISBN: 978-84-124742-0-6, España.

– Peripapillary pachychoroid syndrome coincident to a presumed pulsating extramacular choroidal macrovessel, Clinical and Experimental Optometry, 106:6, 683-685, DOI: 10.1080/08164622.2022.2071603.

 – Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2023.114368.

actividades formativas

 

– Profesor Colaborador de Oftalmología durante el curso 2021-2022. Universidad de Córdoba, España.

– Tutor de residentes de la unidad de oftalmología del Hospital Universitario Reina Sofía, Córdoba, España..

Experiencia en Ensayos clinicos

 

Como Sub-investigador:

1. A Randomized, Double-Masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) In Subjects with Neovascular Age-Related Macular Degeneration. Amgen. Phase 3. Code: 20170542.

2. Randomized, Double-Masked, Active-Controlled, Multi-Center Study of Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration. Bayer. Phase 3. Code: 20968.

3. Efficacy And Safety Assessment of T4030 Eye Drops Versus Ganfort® UD In Ocular Hypertensive or Glaucomatous Patients. Théa. Phase 3. Code: LT4030-301.

4. Randomized Single-Blind Clinical Trial to Evaluate the Tolerability, Efficacy, Quality of Life, And Adherence of Preservative-Free Latanoprost/Timolol (Fixaprost) Compared to Preserved Bimatoprost/Timolol (Ganfort) In Patients with Open-Angle Glaucoma or Ocular Hypertension. Théa. Phase 3. Code: ADEQUATE.

5. An Extension Trial to Evaluate the Long-Term Safety and Efficacy of Bimatoprost SR in With Patient with Open Angle or Ocular Hypertension. ALLERGAN. Phase 3. Code: 1698-302-007.

Como Colaborador:

1. Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy Of AT-001 In Patients with Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure). Applied Therapeutics, Inc. Phase 3. Code: AT-001-201 (ARISE).

2. Effects Of Semaglutide on Functional Capacity in Patients with Type 2 Diabetes and Peripheral Arterial Disease. Novo Nordisk. Phase 3b. Code: NN9535-4533 (STRIDE).

3. A Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes. Novo Nordisk. Phase 3. Code: EX9924-4473 (SOUL).

4. A Phase 2b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, And Open-Label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus. Astrazeneca. Phase 2B. Code: D5676C00001.

5. A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) In Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with Brain Metastases And/Or Leptomeningeal Carcinomatosis. MEDSIR. Phase 2. Code: Medopp243 (DEBBRAH).

6. A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations. Janssen-Cilag International NV. Phase 3. Code: 42756493BLC3001 (THOR).

7. Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for The Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302). QED Therapeutics, Inc. Phase 3. Code: QBGJ398-302 (PROOF).

8. A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. Immunogen, Inc. Phase 3. Code: SORAYA.

9. An Open-Label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Seagen, Inc. Phase 3. Code: SGN22E-003 (EV-302).

10. Open-Label, Multicenter, Non-Randomized, Phase 2 Study to Determine the Safety, Tolerability and Efficacy of Encorafenib Given in Combination with Binimetinib in Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC). ARRAY Biopharma. Phase 2. Code: Array 818-202.

11. A Phase II, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-Dxd, DS-8201a) For the Treatment of Selected HER2-Expressing Tumors (DESTINY-Pantumor02). Astrazeneca. Phase 2. Code: D967VC00001 (DESTINY PANTUMOR02).

12. A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement (FIGHT-302). Incyte. Phase 3. Code: FIGHT-302.

13. A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Vs Investigator’s Choice Chemotherapy in Secondor Third-Line Recurrent or Metastatic Cervical Cancer. Seagen, Inc. Phase 3. Code: SGNTV-003.

14. A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201). Verastem, Inc; ENGOT; GOG Foundation. Phase 2. Code: VS-6766-201.

15. A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma. F. Hoffmann-La Roche Ltd. Phase 1B/2. Code: WO39613 (MORPHEUS-UC).

16. A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. Immunogen, Inc. Phase 2. Code: IMGN853-0419.

17. A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAFV600e/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma. Pfizer. Phase 3. Code: C4221016.

18. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression. AMGEN. Phase 3. Code: 20210096 FORTITUDE-101.

19. A Phase 3, Randomized, Multi-Center, Open-Label Study of Trastuzumab Deruxtecan (T-Dxd) Versus Investigators Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in The Metastatic Setting (DESTINY-Breast06). Astrazeneca. Phase 3. Code: D9670C00001.

Pide tu cita

12 + 12 =